Ipilimumab and nivolumab: the ‘new kid on the block’ in advanced angiosarcoma

References

• 1. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 11(10), 983–991 (2010).
  MedlineGoogle Scholar
• 2. Sturm EC, Marasco IS, Katz SC. Multidisciplinary management of angiosarcoma – a review. J. Surg. Res. 257, 213–220 (2021).
  Medline CASGoogle Scholar
• 3. Penel N, Bui BN, Bay J-O et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26(32), 5269–5274 (2008).
  Medline CASGoogle Scholar
• 4. Soft Tissue Sarcoma. National Comprehensive Cancer Network, Plymouth Meeting, PA, USA (2023).
  Google Scholar
• 5. Tawbi HA, Burgess M, Bolejack V et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18(11), 1493–1501 (2017).
  Medline CASGoogle Scholar
• 6. D'Angelo SP, Mahoney MR, Van Tine BA et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 19(3), 416–426 (2018).
  MedlineGoogle Scholar
• 7. Toulmonde M, Penel N, Adam J et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 4(1), 93–97 (2018).
  MedlineGoogle Scholar
• 8. Wilky BA, Trucco MM, Kolonias D et al. A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS). J. Clin. Oncol. 36(Suppl. 15), S11547–S11547 (2018).
  Google Scholar
• 9. Wang D-R, Wu X-L, Sun Y-L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Sig. Transduct. Target Ther. 7(1), 1–27 (2022).
  MedlineGoogle Scholar
• 10. Guan L, Palmeri M, Groisberg R. Cutaneous angiosarcoma: a review of current evidence for treatment with checkpoint inhibitors. Front. Med. (Lausanne) 10, 1090168 (2023).
  MedlineGoogle Scholar
• 11. Espejo-Freire AP, Elliott A, Rosenberg A et al. Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis. Cancers 13(19), 4816 (2021).
  Medline CASGoogle Scholar
• 12. Hamacher R, Kämpfe D, Reuter-Jessen K et al. Dramatic response of a PD-L1-positive advanced angiosarcoma of the scalp to pembrolizumab. JCO Precis. Oncol. 2, 1–7 (2018).
  MedlineGoogle Scholar
• 13. Nathenson MJ, Hornick JL. Complete pathologic response to pembrolizumab in a patient with cutaneous angiosarcoma: case report. J. Hematol. Oncol. Pharm. 12(5), 278–282 (2022).
  Google Scholar
• 14. Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy – a case report. J. Immunother. Cancer 5(1), 58 (2017).
  MedlineGoogle Scholar
• 15. Hofer S, Zeidler K, Schipf A, Kempf W, Zimmermann D, Aebi S. Angiosarcoma of the scalp responding to nivolumab: a case report. Br. J. Dermatol. 179(2), 530–531 (2018).
  Medline CASGoogle Scholar
• 16. Florou V, Rosenberg AE, Wieder E et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J. Immunother. Cancer 7, 1–8 (2019).
  MedlineGoogle Scholar
• 17. Rosenbaum E, Antonescu CR, Smith S et al. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. J. Immunother. Cancer 10(4), e004149 (2022).
  MedlineGoogle Scholar
• 18. Ravi V, Subramaniam A, Zheng J et al. Clinical activity of checkpoint inhibitors in angiosarcoma: a retrospective cohort study. Cancer 128(18), 3383–3391 (2022).
  Medline CASGoogle Scholar
• 19. Wagner MJ, Othus M, Patel SP et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J. Immunother. Cancer 9(8), e002990 (2021).
  MedlineGoogle Scholar
• 20. Seong G, D'Angelo SP. New therapeutics for soft tissue sarcomas: overview of current immunotherapy and future directions of soft tissue sarcomas. Front. Oncol. 13, 1150765 (2023).
  Medline CASGoogle Scholar